The upregulation of TGF-β could be seen as having mixed effects in psoriasis as TGF-β also promotes T cell differentiation towards Th17 phenotypes [45], where T cell and neutrophil-derived IL-17A is seen as a pivotal pro-psoriatic cytokine [46] and therapeutic agents targeting IL-17 or anti-IL-17 monoclonal antibodies have been proven to be effective in the treatment of psoriasis [47,48]. Here, IL17A is linked to psoriasis.